TRIP13 and neoplasm: Blocking of this axis, EMT, NF‐κB and Wnt/β‐catenin signalling by DCZ0415 reduced CRC progression, indicating that DCZ0415 is a potential inhibitor of CRCs exhibiting TRIP13 overexpression and suggests a valid future therapeutic strategy for CRC tumours overexpressing TRIP13.